إعلان
إعلان

ATOS

ATOS logo

Atossa Therapeutics, Inc. Common Stock

0.65
USD
برعاية
-0.01
-1.07%
٠٩ يناير, ١٥:٥٩ UTC -5
مغلق
exchange

بعد الإغلاق

0.64

-0.01
-1.08%

تقارير أرباح ATOS

النسبة الإيجابية المفاجئة

ATOS تفوق 20 من 31 آخر التقديرات.

65%

التقرير التالي

بيانات التقرير القادم
٢٣ مارس ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.06
التغير الضمني من Q3 25 (Revenue/ EPS)
--
/
-14.29%
التغير الضمني من Q4 24 (Revenue/ EPS)
--
/
+20.00%

Atossa Therapeutics, Inc. Common Stock earnings per share and revenue

On ١٢ نوفمبر ٢٠٢٥, ATOS reported earnings of -0.07 USD per share (EPS) for Q3 25, missing the estimate of -0.06 USD, resulting in a -2.94% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -1.74% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 5 المحللين forecast an EPS of -0.06 USD, with revenue projected to reach -- USD, implying an نقصان of -14.29% EPS, and زيادة of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
AngioDynamics, Inc.
Report Date
٠٦ يناير ٢٠٢٦ إلى ربع سنوي2 26
تقدير
-$0.10
الفعلي
$0.00
مفاجئة
+100.00%
الأسئلة الشائعة
For Q3 2025, Atossa Therapeutics, Inc. Common Stock reported EPS of -$0.07, missing estimates by -2.94%, and revenue of $0.00, 0% as expectations.
The stock price moved down -1.74%, changed from $0.83 before the earnings release to $0.81 the day after.
The next earning report is scheduled for ٢٣ مارس ٢٠٢٦.
Based on 5 المحللين, Atossa Therapeutics, Inc. Common Stock is expected to report EPS of -$0.06 and revenue of -- for Q4 2025.
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان